David Vaughan

A 1-Year Community-Based Health Economic Study of Ciprofloxacin vs Usual Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis

Ronald F. Grossman, Jayanti Mukherjee, David Vaughan et al. · CHEST Journal · 1998 · 147 citations

Acute Exacerbations, Usual Antibiotic Treatment, Antibiotics +8

Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension

Anita Shah, Ming-Chung Liu, David Vaughan et al. · Journal of Antimicrobial Chemotherapy · 1999 · 47 citations · Full text

Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year

George W. Torrance, Valery Walker, Ronald F. Grossman et al. · PharmacoEconomics · 1999 · 42 citations

Health Economics, Antibiotics, Chronic Bronchitis +5

Reduced Requirement for Antibiotic Therapy Targeting Gram-Negative Organisms in Febrile, Neutropenic Patients with Cancer Who Are Receiving Antibacterial Chemoprophylaxis with Oral Quinolones

Eric J. Bow, R. Loewen, David Vaughan · Clinical Infectious Diseases · 1995 · 37 citations

Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents

Joseph M. Blondeau, David Vaughan, Roman A. Laskowski et al. · International Journal of Antimicrobial Agents · 2001 · 31 citations

Antibiotics, Healthcare-associated Infection, Klebsiella Pneumoniae +9